BCLI

Brainstorm Cell Therapeutics, Inc

Jul 16 • 04:00PM ET

1.20

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX GILD CRSP FATE SRPT EDIT BLUE NTLA SGMO ADAP

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.98	Insider Own	22.32%	Shs Outstand	7.91M	Perf Week	-3.23%
Market Cap	11.81M	Forward P/E	-	EPS next Y	-0.93	Insider Trans	0.00%	Shs Float	7.64M	Perf Month	9.09%
Enterprise Value	11.94M	PEG	-	EPS next Q	-0.37	Inst Own	10.40%	Short Float	7.91%	Perf Quarter	54.62%
Income	-11.09M	P/S	-	EPS this Y	30.74%	Inst Trans	0.32%	Short Ratio	0.45	Perf Half Y	-40.59%
Sales	0.00M	P/B	-	EPS next Y	41.88%	ROA	-320.45%	Short Interest	0.60M	Perf YTD	-47.14%
Book/sh	-0.94	P/C	7.20	EPS next 5Y	29.48%	ROE	-	52W High	6.30 -80.95%	Perf Year	-80.95%
Cash/sh	0.17	P/FCF	-	EPS past 3/5Y	38.88% 32.00%	ROIC	-	52W Low	0.72 65.91%	Perf 3Y	-97.15%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.61% 7.56%	Perf 5Y	-99.38%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	59.38%	Oper. Margin	-	ATR (14)	0.09	Perf 10Y	-97.77%
Dividend Ex-Date	-	Quick Ratio	0.21	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.66	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.21	EPS Q/Q	42.69%	SMA20	1.52%	Beta	0.13	Target Price	6.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	1.63%	Rel Volume	0.16	Prev Close	1.20
Employees	27	LT Debt/Eq	-	Earnings	May 15 AMC	SMA200	-24.40%	Avg Volume	1.35M	Price	1.20
IPO	May 28, 2003	Option/Short	No / Yes	EPS/Sales Surpr.	53.61% -	Trades		Volume	221,786	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-04-21	Upgrade	Maxim Group	Hold → Buy	$12
Nov-17-20	Downgrade	Maxim Group	Buy → Hold
Dec-19-16	Reiterated	Maxim Group	Buy	$5 → $6
Dec-22-15	Reiterated	Maxim Group	Buy	$14 → $5

Jul-08-25 07:00AM	FDA Review of Citizen Petition Offers a Fresh Look at NurOwn's Evidence of Treatment Effectiveness (PR Newswire) +14.91%
Jun-16-25 08:30AM	BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn (PR Newswire) +12.73%
May-28-25 05:36AM	BrainStorm Cell Therapeutics and Minaris partner on manufacturing NurOwn for trial (Clinical Trials Arena)
May-27-25 07:00AM	BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn Phase 3b ALS Clinical Trials (PR Newswire)
May-20-25 07:24AM	FDA grants clearance to BrainStorms Phase IIIb trial of ALS treatment (Clinical Trials Arena) -8.82%
03:03AM	Loading…
03:03AM	Brainstorm Cell Therapeutics Inc (BCLI) Q1 2025 Earnings Call Highlights: Pivotal Phase 3b ... (GuruFocus.com)
May-19-25 10:32PM	Q1 2025 Brainstorm Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:00AM	BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn for ALS (PR Newswire)
May-15-25 04:05PM	BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire) +13.79%
07:30AM	BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19 (PR Newswire)
May-07-25 06:30AM	BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 (PR Newswire)
May-06-25 07:00AM	BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit (PR Newswire)
Apr-29-25 06:30AM	BrainStorm's NurOwn Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting (PR Newswire)
Apr-10-25 07:30AM	BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn in ALS (PR Newswire) -18.03%
Apr-01-25 03:01AM	Brainstorm Cell Therapeutics Inc (BCLI) Q4 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com) -5.56%
11:41PM	Loading…
Mar-31-25 11:41PM	Q4 2024 Brainstorm Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +5.88%
10:48AM	Brainstorm Cell Therapeutics Inc. (BCLI) Q4 2024 Earnings Call Transcript (Seeking Alpha)
07:00AM	BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update (PR Newswire)
Mar-26-25 08:15AM	BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq (PR Newswire)
Mar-24-25 07:00AM	BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update (PR Newswire)
Dec-30-24 08:00AM	BrainStorm Issues 2024 Letter to Shareholders (PR Newswire)
Dec-09-24 07:00AM	BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update (PR Newswire)
Dec-03-24 07:00AM	BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology (PR Newswire)
Dec-02-24 07:00AM	BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024 (PR Newswire)
Nov-14-24 04:30PM	BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) +7.08%
Nov-11-24 06:00AM	BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn Phase 3b Trial Manufacturing (PR Newswire)
Oct-30-24 06:00AM	BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Oct-28-24 06:00AM	BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn Expanded Access Program at 2024 Annual NEALS Meeting (PR Newswire)
Oct-07-24 07:00AM	BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn Trial at the 2024 Maxim Healthcare Virtual Summit (PR Newswire)
Sep-24-24 06:00AM	BrainStorm Cell Therapeutics Announces Presentations on NurOwn at 2024 Annual NEALS Meeting (PR Newswire)
12:07PM	Loading…
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire) -5.67%
Aug-14-24 07:05AM	BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Aug-07-24 06:00AM	BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update (PR Newswire)
Jul-24-24 08:30AM	BCLI Update - Progress Supports Our 10x Plus Value Range Potential (PR Newswire) +6.10%
Jul-01-24 06:00AM	BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program (PR Newswire) +5.47%
Jun-27-24 09:15AM	BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering (PR Newswire) -7.87%
Jun-26-24 08:00AM	BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn Clinical Trial (PR Newswire)
Jun-20-24 06:00AM	BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer (PR Newswire)
Jun-14-24 12:01PM	BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn Clinical Effectiveness Expectation (PR Newswire) +6.09%
May-20-24 06:00AM	BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn (PR Newswire) +9.02%
May-14-24 10:53PM	BCLI Stock Earnings: Brainstorm Cell Reported Results for Q1 2024 (InvestorPlace) -8.74%
04:30PM	BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-01-24 07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +15.10%
Apr-16-24 06:30PM	BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn (PR Newswire)
Apr-11-24 06:00AM	BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule (PR Newswire)
Apr-10-24 06:00AM	BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's Phase 3 Clinical Trial in ALS (PR Newswire)
Apr-09-24 06:00AM	BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS (PR Newswire) -20.21%
Apr-08-24 06:00AM	BrainStorm Cell Therapeutics to Provide Update on NurOwn Program (PR Newswire) +12.14%
Apr-01-24 08:05AM	BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update (PR Newswire) +31.03%
Feb-27-24 06:30AM	BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn Trial Design at MDA Clinical and Scientific Conference (PR Newswire)
Feb-23-24 06:00AM	BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn in ALS (PR Newswire) +5.60%
Feb-13-24 06:30AM	BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum (PR Newswire) -5.63%
Dec-27-23 09:30AM	BRAINSTORM SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options (GlobeNewswire) +24.35%
Dec-26-23 07:30AM	BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments (PR Newswire) +16.40%
Dec-20-23 09:00AM	BrainStorm Issues 2023 Letter to Shareholders (PR Newswire)
Dec-07-23 08:40AM	BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn in ALS (PR Newswire) -25.33%
Nov-20-23 08:10AM	BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn in ALS (PR Newswire)
Nov-17-23 07:00AM	BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia (PR Newswire)
Nov-15-23 01:53PM	Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2023 Earnings Call Transcript (Insider Monkey)
03:29AM	Q3 2023 Brainstorm Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 07:05AM	BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-08-23 08:00AM	BRAINSTORM SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options (PR Newswire)
Nov-07-23 06:00AM	BrainStorm to Announce Third Quarter 2023 Financial Results and Provide a Corporate Update (PR Newswire) +10.82%
Oct-24-23 07:00AM	BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn for the Treatment of ALS (PR Newswire) -8.28%
Oct-23-23 10:05AM	BCLI: Meeting with FDA to Discuss Development Plan for NurOwn® (Zacks) -5.67%
Oct-18-23 08:01AM	BrainStorm, after setbacks, withdraws approval application for ALS drug (BioPharma Dive)
06:00AM	BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS (PR Newswire)
Oct-02-23 07:00AM	BCLI: Advisory Panel Votes Against Recommending Approval of NurOwn® (Zacks)
Sep-27-23 10:48PM	BrainStorm Cell Therapeutics Provides Update on FDA Advisory Committee Meeting to Review NurOwn for the Treatment of ALS (PR Newswire)
06:15PM	FDA advisers vote against experimental ALS treatment pushed by patients (Associated Press Finance)
07:00AM	BrainStorm Cell Therapeutics Stock Trading Halted Today (PR Newswire)
Sep-26-23 12:17PM	BCLI: Public Support for NurOwn® from Prominent ALS Specialists (Zacks) -8.35%
Sep-25-23 08:13AM	FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy (Reuters) -47.57%
Aug-18-23 08:34AM	BCLI: Preparing for AdCom on September 27, 2023 (Zacks)
Aug-15-23 03:11AM	Q2 2023 Brainstorm Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.59%
Aug-14-23 07:05AM	BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Aug-07-23 04:05PM	BrainStorm to Announce Second Quarter 2023 Financial Results and Provide a Corporate Update (PR Newswire)
Jul-17-23 09:15AM	Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering (PR Newswire) -5.58%
Jul-12-23 07:00AM	BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer (PR Newswire)
Jul-07-23 07:00AM	BrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of Neurodegeneration (PR Newswire)
Jun-20-23 09:06AM	BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair (PR Newswire) -14.12%
Jun-16-23 07:00AM	BrainStorm Cell Therapeutics to Participate in the Maxim Group Healthcare Virtual Conference (PR Newswire)
Jun-06-23 06:00AM	BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review NurOwn® Biologics License Application Scheduled for September 27, 2023 (PR Newswire)
May-23-23 11:35AM	BCLI: Awaiting Adcom Date for NurOwn® (Zacks Small Cap Research)
May-19-23 07:30AM	BrainStorm Cell Therapeutics Summarizes Key Messages from Its Participation as Expert Speakers in an Invited Presentation and Panel Discussion at The 2023 ALS Drug Development Summit (PR Newswire)
May-18-23 08:55AM	While institutions own 23% of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), retail investors are its largest shareholders with 59% ownership (Simply Wall St.)
May-17-23 02:41PM	Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-15-23 07:05AM	BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
May-09-23 06:00AM	BrainStorm to Announce First Quarter 2023 Financial Results and Provide a Corporate Update (PR Newswire)
Apr-24-23 07:00AM	BrainStorm Cell Therapeutics Strengthens Leadership Team with Appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer (PR Newswire)
Apr-07-23 07:30AM	Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Apr-05-23 07:46PM	Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2022 Earnings Call Transcript (Insider Monkey) +5.62%
Apr-04-23 09:12AM	BCLI: Preparing for Adcom for NurOwn® (Zacks Small Cap Research) -10.70%
Mar-30-23 07:05AM	BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update (PR Newswire)
Mar-27-23 09:15AM	BCLI: FDA Grants Adcom for NurOwn® (Zacks Small Cap Research)
06:00AM	BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn® for the Treatment of ALS (PR Newswire)
Mar-21-23 08:18AM	BrainStorm to Announce Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update (PR Newswire)
Jan-10-23 07:00AM	BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn's Phase 3 ALS Study (PR Newswire)
Jan-05-23 07:30AM	BrainStorm Cell Therapeutics to Present at Biotech Showcase 2023 (PR Newswire) -5.52%
Jan-04-23 07:30AM	BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer (PR Newswire)

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lebovits Chaim	President & CEO	Oct 01 '24	Buy	3.43	1,836	6,292	80,960	Oct 02 08:00 AM
Lebovits Chaim	President & CEO	Sep 30 '24	Buy	0.23	22,000	5,016	1,186,865	Oct 02 08:00 AM
Dagher Ibrahim B.	Chief Medical Officer	Jul 19 '24	Sale	0.35	63,000	22,069	0	Jul 24 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCLI

Brainstorm Cell Therapeutics, Inc

Upgrade your FINVIZ experience